

Technological milestones update - CCL units

Released : 31.07.2017

RNS Number : 5067M
Advanced Oncotherapy PLC
31 July 2017

ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")

Technological milestones update - CCL units

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the completion of a further technological milestone in the manufacture of its first LIGHT system.

Delivery of CCLs

The Company confirms that the final Coupled Cavity Linac (CCL) module, to be used to generate a beam capable of treating superficial tumours when integrated with the LIGHT system's other components, is ready for shipment to the Geneva testing facility; the other CCL modules are on site.

The CCLs are an integral component of LIGHT and are the final accelerating structures after the proton source, the Radio Frequency Quadrupole ("RFQ") and Side Coupled Drift Tube Linacs ("SCDTLs"). The CCLs will undergo further testing before being conditioned and prepared for integration with the SCDTLs in 2018.

The LIGHT system's development remains on track for LIGHT to produce a proton beam capable of treating superficial tumours by the end of Q3 2018, with the beam expected to be fired through the first CCL by the end of Q2 2018. Work continues on the integration of the SCDTLs with the RFQ, with the first beam through the SCDTLs expected by the end of the year.

The integration of the components that will form the Patient Positioning System continues apace and is also expected to advance significantly in the coming months.

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said *"The successful manufacture, performance testing and now delivery of the CCLs are a major milestone in the technological development of the LIGHT system. For the first time, we will now have all of the key high-speed accelerating modules for LIGHT in place in our Geneva site and with a great deal of the manufacturing risk behind us, we can focus on the integration and commissioning of the individual components. This development brings the reality of the world's first linear proton accelerator in the treatment of cancer much closer."*

www.avoplc.com

Advanced Oncotherapy Plc

Dr. Michael Sinclair, Executive Chairman
Nicolas Serandour, CEO

Tel: +44 20 3617 8728

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Paul McManus / Anna Dunphy

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater

precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCSDMFASFWSEFW